These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 20113982)

  • 21. Human papillomavirus vaccines versus cervical cancer screening.
    Stanley M
    Clin Oncol (R Coll Radiol); 2008 Aug; 20(6):388-94. PubMed ID: 18538554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prophylactic HPV vaccination: a major breakthrough in the fight against cervical cancer?
    Saleem A; Tristram A; Fiander A; Hibbitts S
    Minerva Med; 2009 Dec; 100(6):503-23. PubMed ID: 20010484
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancers attributable to human papillomavirus infection.
    Grulich AE; Jin F; Conway EL; Stein AN; Hocking J
    Sex Health; 2010 Sep; 7(3):244-52. PubMed ID: 20719211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
    Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
    BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cervical cancer control in the era of HPV vaccination and novel biomarkers.
    Wentzensen N; Klug SJ
    Pathobiology; 2009; 76(2):82-9. PubMed ID: 19367128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none.
    El-Zein M; Richardson L; Franco EL
    J Clin Virol; 2016 Mar; 76 Suppl 1(Suppl 1):S62-S68. PubMed ID: 26631958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Declining rates of cervical intraepithelial neoplasia in British Columbia, Canada: An ecological analysis on the effects of the school-based human papillomavirus vaccination program.
    Donken R; van Niekerk D; Hamm J; Spinelli JJ; Smith L; Sadarangani M; Albert A; Money D; Dobson S; Miller D; Lee M; Mitchell-Foster S; Krajden M; Naus M; Ogilvie G
    Int J Cancer; 2021 Jul; 149(1):191-199. PubMed ID: 33586169
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Methods of cervical cancer screening and facing new problems in China].
    Zhang WH
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):881-4. PubMed ID: 19173985
    [No Abstract]   [Full Text] [Related]  

  • 29. Human papillomavirus vaccination and subsequent cervical cancer screening in a large integrated healthcare system.
    Chao C; Silverberg MJ; Becerra TA; Corley DA; Jensen CD; Chen Q; Quinn VP
    Am J Obstet Gynecol; 2017 Feb; 216(2):151.e1-151.e9. PubMed ID: 27746152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.
    Paavonen J; Naud P; Salmerón J; Wheeler CM; Chow SN; Apter D; Kitchener H; Castellsague X; Teixeira JC; Skinner SR; Hedrick J; Jaisamrarn U; Limson G; Garland S; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Jenkins D; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
    Lancet; 2009 Jul; 374(9686):301-14. PubMed ID: 19586656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types.
    McKeage K; Romanowski B
    Drugs; 2011 Mar; 71(4):465-88. PubMed ID: 21395359
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modeling the impact of screening policy and screening compliance on incidence and mortality of cervical cancer in the post-HPV vaccination era.
    de Blasio BF; Neilson AR; Klemp M; Skjeldestad FE
    J Public Health (Oxf); 2012 Dec; 34(4):539-47. PubMed ID: 22707556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of HPV vaccination in the prevention of cervical cancer in Malaysia.
    Ezat WP; Aljunid S
    Asian Pac J Cancer Prev; 2010; 11(1):79-90. PubMed ID: 20593935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A nationwide birth year-by-year analysis of effectiveness of HPV vaccine in Japan.
    Yagi A; Ueda Y; Nakagawa S; Masuda T; Miyatake T; Ikeda S; Abe H; Hirai K; Sekine M; Miyagi E; Enomoto T; Nakayama T; Kimura T
    Cancer Sci; 2021 Sep; 112(9):3691-3698. PubMed ID: 34252250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of preventive HPV vaccination.
    Roden R; Monie A; Wu TC
    Discov Med; 2006 Oct; 6(35):175-81. PubMed ID: 17234138
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015.
    Cleveland AA; Gargano JW; Park IU; Griffin MR; Niccolai LM; Powell M; Bennett NM; Saadeh K; Pemmaraju M; Higgins K; Ehlers S; Scahill M; Johnson Jones ML; Querec T; Markowitz LE; Unger ER;
    Int J Cancer; 2020 Feb; 146(3):810-818. PubMed ID: 30980692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Papillomavirus vaccine types 16 and 18: new drug. Cervical cancer: just another vaccine.
    Prescrire Int; 2008 Jun; 17(95):103-4. PubMed ID: 18623911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study).
    Young EJ; Tabrizi SN; Brotherton JM; Wark JD; Pyman J; Saville M; Wrede CD; Jayasinghe Y; Tan J; Gertig DM; Pitts M; Garland SM
    BMC Cancer; 2013 Jun; 13():296. PubMed ID: 23777549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model.
    Usher C; Tilson L; Olsen J; Jepsen M; Walsh C; Barry M
    Vaccine; 2008 Oct; 26(44):5654-61. PubMed ID: 18723068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design of a long-term follow-up effectiveness, immunogenicity and safety study of women who received the 9-valent human papillomavirus vaccine.
    Luxembourg A; Kjaer SK; Nygard M; Ellison MC; Group T; Marshall JB; Radley D; Saah A
    Contemp Clin Trials; 2017 Jan; 52():54-61. PubMed ID: 27777126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.